Compare Revvity Inc (RVTY) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Shell PLC — how do they compare? Revvity Inc trades at $154.72 (market cap $16.98B), while Shell PLC trades at $100.19 (market cap $284.34B). The key difference: Shell PLC is far larger — about 16.7× Revvity Inc's market cap, and Shell PLC pays the higher dividend (3.12%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Shell PLC for 90 Days on average.
| RVTY | SHEL | |
|---|---|---|
Market Cap | $16.98B | $284.34B |
Volume | 1,456,900 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $157.36 | $100.20 |
52-Week Low | $82.26 | $70.31 |
Typical Hold Time | 12 Days | 90 Days |
Enterprise Value | $19.30B | $326.04B |
Dividend Yield | 0.18% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Shell (SHEL) trades at $100.56, up 3.83% today, approaching its 52-week high. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows bullish technical signals, supported by strong cash flow and a 61.5% analyst buy rating. Key developments include the LNG Canada Phase 2 expansion, doubling export capacity, and new carbon capture deals, highlighting strategic growth in energy transition assets.
Outlook remains positive with valuation metrics like P/E of 11.08 and EV/EBITDA of 4.8 suggesting room for upside toward the $102.53 consensus target. Risks include volatile oil prices and execution challenges in new projects, but robust LNG demand and portfolio optimization provide a solid foundation for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
